



Table S1. Univariate Cox proportional hazards model in patients with Hs-CRP < 2 mg/L.

Parameter	Primary Outcome		Ischemic Events		Heart Failure/Death	
	HR (95%CI)	p-Value	HR (95%CI)	p-Value	HR (95%CI)	p-Value
Age, years	1.05 (1.03–1.07)	<0.001	1.02 (1.00–1.04)	0.055	1.11 (1.07–1.14)	<0.001
Sex, male	0.91 (0.58–1.44)	0.911	0.91 (0.51–1.61)	0.911	1.25 (0.65–2.39)	0.499
Smoker, yes	1.44 (0.95–2.19)	0.085	1.78 (1.07–2.97)	0.027	1.07 (0.56–2.04)	0.846
Body mass index, kg/m ²	1.00 (1.00–1.00)	0.951	1.00 (0.97–1.02)	0.946	0.95 (0.88–1.03)	0.202
Diabetes, yes	1.92 (1.25–2.96)	0.003	1.59 (0.92–2.77)	0.097	2.95 (1.63–5.37)	<0.001
Hypertension, yes	2.70 (1.62–4.52)	<0.001	2.29 (1.24–4.22)	0.008	4.56 (1.80–11.5)	0.001
History of CVE, yes	3.52 (1.43–8.69)	0.006	3.01 (0.94–9.63)	0.063	4.35 (1.34–14.0)	0.014
Ejection fraction <40%, yes	2.07 (1.19–3.60)	0.010	1.58 (0.75–3.32)	0.230	4.48 (2.31–8.72)	<0.001
Atrial Fibrillation, yes	1.23 (0.57–2.66)	0.598	0.82 (0.26–2.61)	0.733	2.05 (0.81–5.21)	0.131
Acute myocardial infarction, yes	0.74 (0.49–1.13)	0.163	0.53 (0.31–0.92)	0.023	1.22 (0.67–2.22)	0.512
Complete Revascularization	0.70 (0.46–1.06)	0.089	0.71 (0.42–1.19)	0.196	0.62 (0.34–1.14)	0.123
LDL-c, mg/dL	1.00 (1.00–1.01)	0.759	1.00 (0.99–1.01)	0.434	0.98 (0.97–1.00)	0.037
HDL-c, mg/dL	0.99 (0.97–1.01)	0.387	0.99 (0.96–1.01)	0.362	1.00 (0.97–1.03)	0.989
Triglycerides, mg/dL	1.00 (1.00–1.00)	0.493	1.00 (1.00–1.01)	0.063	0.99 (0.98–1.00)	0.076
CKD-EPI <60 mL/min/1.73 m ²	2.48 (1.58–3.87)	<0.001	2.19 (1.24–3.87)	0.007	3.36 (1.82–6.21)	<0.001
Acetylsalicylic acid, yes	0.68 (0.33–1.41)	0.306	1.22 (0.38–3.91)	0.732	0.51 (0.20–1.29)	0.154
AntiP2Y12, yes	0.71 (0.46–1.10)	0.115	0.97 (0.54–1.73)	0.909	0.68 (0.36–1.27)	0.231
Anticoagulants, yes	2.08 (0.96–4.50)	0.062	1.36 (0.43–4.35)	0.602	4.20 (1.77–9.95)	0.001
Statins, yes	0.31 (0.17–0.59)	<0.001	0.53 (0.21–1.31)	0.169	0.23 (0.10–0.52)	<0.001
ACE inhibitors, yes	0.62 (0.42–0.93)	0.021	0.51 (0.31–0.84)	0.009	1.08 (0.59–1.98)	0.800
ARB, yes	2.32 (1.49–3.63)	<0.001	2.62 (1.53–4.51)	<0.001	1.52 (0.75–3.09)	0.241
Anti-aldosterone, yes	2.17 (1.19–3.99)	0.012	1.53 (0.66–3.55)	0.326	5.31 (2.67–10.6)	<0.001
β-Blockers, yes	0.44 (0.29–0.66)	<0.001	0.56 (0.33–0.96)	0.034	0.28 (0.15–0.50)	<0.001
Nitrates, yes	2.26 (1.42–3.58)	0.001	2.19 (1.22–3.94)	0.009	2.58 (1.36–4.88)	0.004
Diuretics, yes	2.04 (1.31–3.19)	0.002	1.40 (0.76–2.58)	0.287	3.83 (2.11–6.70)	<0.001
Insulin, yes	2.53 (1.31–4.89)	0.006	2.71 (1.23–5.97)	0.013	3.03 (1.28–7.20)	0.012
Oral antidiabetic drugs, yes	1.69 (1.02–2.80)	0.041	1.25 (0.63–2.46)	0.518	2.19 (1.11–4.34)	0.025
NT-proBNP, 1-SD	1.40 (1.25–1.57)	<0.001	1.15 (0.96–1.37)	0.127	1.69 (1.48–1.91)	<0.001
MCP-1, 1-SD	1.27 (1.10–1.46)	0.001	1.08 (0.85–1.37)	0.545	1.41 (1.20–1.67)	<0.001
Gal-3, 1-SD	1.11 (0.99–1.25)	0.075	1.11 (0.95–1.29)	0.191	1.14 (0.98–1.33)	0.080
Tn-I, 1-SD	1.12 (0.93–1.35)	0.237	0.81 (0.41–1.58)	0.529	1.25 (1.05–1.48)	0.010

Table S2. Univariate Cox proportional hazards model in patients with Hs-CRP $\geq$ 2 mg/L.

Parameter	Primary Outcome		Ischemic Events		Heart Failure/Death	
	HR (95%CI)	p-Value	HR (95%CI)	p-Value	HR (95%CI)	p-Value
Age, years	1.04 (1.02–1.06)	<0.001	1.01 (0.99–1.04)	0.192	1.09 (1.06–1.12)	<0.001
Sex, male	0.63 (0.40–1.00)	0.048	0.64 (0.36–1.13)	0.640	1.84 (1.03–3.28)	0.039
Smoker, yes	1.60 (0.99–2.57)	0.054	1.61 (0.89–2.92)	0.118	0.58 (0.31–1.08)	0.084
Body mass index, kg/m ²	1.00 (0.99–1.02)	0.783	1.00 (0.97–1.02)	0.846	1.01 (0.99–1.02)	0.323
Diabetes, yes	1.12 (0.70–1.79)	0.630	1.49 (0.85–2.61)	0.162	1.00 (0.53–1.89)	0.999
Hypertension, yes	1.71 (1.04–2.79)	0.033	1.68 (0.90–3.14)	0.104	2.14 (1.07–4.28)	0.032
History of CVE, yes	1.69 (0.68–4.16)	0.257	0.94 (0.23–3.85)	0.930	3.42 (1.35–8.64)	0.009
Ejection fraction <40%, yes	2.54 (1.60–4.05)	<0.001	1.85 (0.99–3.45)	0.054	4.25 (2.40–7.53)	<0.001
Atrial Fibrillation, yes	3.62 (2.04–6.43)	<0.001	1.39 (0.50–3.85)	0.528	7.16 (3.77–13.6)	<0.001
Acute myocardial infarction, yes	0.63 (0.40–0.99)	0.045	0.57 (0.32–1.02)	0.057	0.84 (0.67–2.22)	0.564
Complete Revascularization	0.49 (0.32–0.75)	0.001	0.48 (0.28–0.81)	0.007	0.46 (0.26–0.80)	0.007
LDL-c, mg/dL	1.01 (1.00–1.01)	0.028	1.01 (1.00–1.02)	0.004	1.00 (0.99–1.01)	0.857
HDL-c, mg/dL	1.02 (1.01–1.04)	0.004	1.01 (0.99–1.03)	0.258	1.03 (1.01–1.05)	0.008
Triglycerides, mg/dL	1.00 (1.00–1.00)	0.560	1.00 (1.00–1.00)	0.276	1.00 (1.00–1.00)	0.841
CKD-EPI <60 mL/min/1.73 m ²	1.51 (0.96–2.38)	0.074	0.92 (0.48–1.74)	0.795	2.73 (1.56–4.78)	<0.001
Acetylsalicylic acid, yes	0.98 (0.47–2.02)	0.948	1.66 (0.52–5.33)	0.393	0.58 (0.26–1.30)	0.190
AntiP2Y12, yes	0.95 (0.61–1.48)	0.814	1.04 (0.58–1.84)	0.904	0.90 (0.50–1.62)	0.723
Anticoagulants, yes	2.61 (1.47–4.62)	0.001	1.26 (0.50–3.16)	0.624	3.98 (2.03–7.80)	<0.001
Statins, yes	0.38 (0.21–0.70)	0.002	0.35 (0.17–0.71)	0.004	0.41 (0.19–0.92)	0.031
ACE inhibitors, yes	0.98 (0.64–1.49)	0.914	0.82 (0.48–1.40)	0.474	1.19 (0.68–2.09)	0.545
ARB, yes	1.40 (0.85–2.31)	0.188	1.06 (0.53–2.11)	0.870	1.79 (0.96–3.32)	0.066
Anti-aldosterone, yes	2.16 (0.99–4.68)	0.052	1.88 (0.68–5.22)	0.227	2.69 (1.06–6.78)	0.036
β -Blockers, yes	0.91 (0.56–1.48)	0.708	1.23 (0.63–2.38)	0.543	0.71 (0.39–1.32)	0.181
Nitrates, yes	2.13 (1.33–3.42)	0.002	1.56 (0.82–2.97)	0.173	2.15 (1.16–4.01)	0.016
Diuretics, yes	1.69 (1.07–2.67)	0.023	1.22 (0.67–2.25)	0.514	2.70 (1.53–4.76)	0.001
Insulin, yes	3.02 (1.67–5.46)	<0.001	3.07 (1.50–6.28)	0.002	3.88 (1.88–8.02)	<0.001
Oral antidiabetic drugs, yes	0.97 (0.57–1.64)	0.898	1.24 (0.67–2.32)	0.494	1.00 (0.50–2.01)	0.989
NT-proBNP, 1-SD	1.37 (1.24–1.51)	<0.001	1.14 (0.94–1.40)	0.188	1.52 (1.38–1.68)	<0.001
MCP-1, 1-SD	1.38 (1.21–1.57)	<0.001	1.34 (1.12–1.60)	0.001	1.29 (1.11–1.50)	0.001
Gal-3, 1-SD	1.40 (1.14–1.72)	0.001	1.24 (0.95–1.62)	0.116	1.87 (1.45–2.41)	<0.001
Tn-I, 1-SD	1.17 (1.06–1.28)	0.001	1.23 (0.97–1.31)	0.120	1.23 (1.12–1.35)	<0.001